Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a su...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Ros, van Diepen, Michiel, Douglass, Nicola, Galant, Shireen, Jaffer, Mohamed, Margolin, Emmanuel, Ximba, Phindile, Hermanus, Tandile, Moore, Penny L., Williamson, Anna-Lise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620012/
https://www.ncbi.nlm.nih.gov/pubmed/34835214
http://dx.doi.org/10.3390/vaccines9111281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620012/
https://www.ncbi.nlm.nih.gov/pubmed/34835214
http://dx.doi.org/10.3390/vaccines9111281

Ejemplares similares